跳至主要内容
临床试验/NCT04720001
NCT04720001已完成不适用

Florbetaben PET Imaging in Primary Progressive Aphasia

University of Chicago1 个研究点 分布在 1 个国家目标入组 1 人开始时间: 2018年8月23日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
1
试验地点
1
主要终点
Amyloid plaque levels in PPA participants

研究概览

简要总结

The purpose of this research is to better understand how dementia affects activity in different parts of the brain.

详细描述

This study will examine Positron Emission Tomography (PET) imaging with Florbetaben F18. Florbetaben F18 is a radioactive tracer that binds to particles in your brain. This process displays activity in the brain. Florbetaben F18 is a PET amyloid imaging agent approved by the United States Food and Drug Administration (FDA) to estimate the amount of beta-amyloid plaque in adult patients who are being evaluated for Alzheimer's disease and other causes of cognitive decline. The purpose of this research is to better understand how dementia affects activity in different parts of the brain. Currently, the scientific community is limited by how well it can see inside the brain. The use of a PET scan better helps us understand what the brain looks like in a diseased state. Participation in the study will help to understand what brain activity looks like, especially around language regions.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 100 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Participants must have a diagnosis of PPA or a related dementia syndrome

排除标准

  • Breastfeeding
  • Receiving radiation clinically

研究组 & 干预措施

Experimental: Florbetaben F18 recipients

Participants in this arm of the study will receive 8.1mCi of florbetaben F18 and then be scanned in a PET scanner for brain imaging.

干预措施: Florbetaben F18 (Drug)

Experimental: Florbetaben F18 recipients

Participants in this arm of the study will receive 8.1mCi of florbetaben F18 and then be scanned in a PET scanner for brain imaging.

干预措施: PET (Device)

结局指标

主要结局

Amyloid plaque levels in PPA participants

时间窗: 2 Years

Amyloid plaque aggregation as measured by florbetaben F18 standard uptake value ratio cerebral and cerebellar regions of interest.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验